11/17/2026 | Press release | Distributed by Public on 11/17/2026 12:48
A wound that won't heal can put a limb at risk. Research co-led by a Rutgers scientist points to a possible way to help the body fight the infections that can keep these wounds open.
In a study published in the journal Life Science Alliance, researchers found that an organic compound called K21 helped human immune cells control bacteria more effectively in laboratory tests. Dentists use K21 in a cavity cleanser cleared by the U.S. Food and Drug Administration (FDA) in 2020 to reduce bacteria before placing fillings and other dental restorations.
"Nonhealing wounds are a major complication for diabetic patients, often leading to amputations, so there is a major need for novel treatments that can heal them," said Christopher Rongo, a professor in the Department of Genetics in the Rutgers School of Arts and Sciences and a member of the university's Waksman Institute of Microbiology.
For a wound to heal, the body must move from fighting infection to repairing damage, said Rongo, an author of the study. Persistent infection can stall that process. The findings may help explain why K21 sped wound healing in earlier studies in mice and rabbits and guide efforts to develop it for patients with wounds that resist treatment.
To investigate how K21 works, the researchers studied macrophages, immune cells that swallow invading microbes. These cells also help coordinate tissue repair, making them important to both fighting infection and healing a wound.
You always hope that what you're working on leads to something that could be helpful for people.
Christopher Rongo
Professor, Department of Genetics
The team treated immune cells from human blood donors with K21, washed away the compound and then exposed the cells to Enterococcus faecalis, a bacterium that can survive inside macrophages.
Fewer bacteria recovered from the treated cells and were able to grow into colonies. The effect was especially apparent in a type of macrophage usually associated with tissue repair. Because the researchers had removed K21 before adding bacteria, the result suggested that the compound had changed the cells' ability to fight infection.
"We could challenge the macrophages with K21, give them a pre-treatment, then give them bacteria, and they're much more robust at killing and clearing that bacteria," Rongo said.
The researchers also used cutting-edge genomics approaches to examine gene activity in individual cells. They found changes in genes involved in how cells use energy and respond to infection, providing clues to what K21 was doing.
Another part of the study focused on mitochondria, tiny structures inside cells that help supply energy and send signals about damage and infection. Cells maintain these structures in part by breaking down and recycling old or damaged mitochondria. Scientists call this process mitophagy.
Mitochondria, the tiny structures that supply cells with energy, are shown inside the gut cells of a living C. elegans roundworm. Normal mitochondria appear in blue-green. Those in magenta are being broken down by the cells' quality-control system in response to K21, a compound the worm was fed.Experiments in human cells and a tiny worm, Caenorhabditis elegans, showed that K21 could stimulate that recycling. In worms, fluorescent markers let the team follow mitochondria as cells broke them down. Treatment increased the recycling without measurable reductions in the worms' growth or fertility.
Rongo said he suspects changes in this cleanup process help explain the stronger defenses against bacteria. Whether K21 also helps immune cells shift from fighting infection to supporting tissue repair still needs to be established.
The investigation emerged from observations in dental care. Dentists working with FiteBac, the company that makes K21, developed the compound to help remove microbes before a tooth is restored. They noticed that tissue also seemed to heal faster after some procedures, Rongo said. Those observations led to studies of wound healing in animals.
Representatives of FiteBac approached Rongo because his laboratory studies mitochondria and how cells maintain them. He teamed up with Bhupesh K. Prusty, an expert in microbial and viral infections affiliated with Riga Stradins University in Latvia and the University of Würzburg in Germany. Together, they co-led the study.
The worm experiments produced an intriguing side finding. The animals lived 36% longer after a single treatment during early development, Rongo said. He viewed that result as another way to test whether stimulating mitochondrial maintenance could benefit a living organism. Rongo cautions that it doesn't establish that K21 would extend human life.
For wound care, Rongo envisions a possible liquid applied to the skin. K21 is used in an FDA-cleared dental cleanser, but it hasn't been cleared to treat wounds, he said. The new study didn't test wound healing on people.
Further research would need to establish whether K21 can safely help patients' wounds heal and how it compares with existing treatments. Rongo's laboratory is also investigating exactly how the compound triggers mitochondrial recycling.
"You always hope that what you're working on leads to something that could be helpful for people," he said.
Eun Chan Park of Rutgers and Claudia Hollmann of the University of Würzburg contributed equally as first authors.
The research was supported in part by the National Institutes of Health and grants from FiteBac to Rongo and Prusty. Rongo holds no stock in the company or intellectual property rights to K21.
Explore more of the ways Rutgers research is shaping the future.